Bank of America this morning maintains a Neutral rating on Dendreon (DNDN).
BofA says it is expecting approval of Provenge by May 15th after chats with folks like a former FDA general counsel and CBER panel members. BofA sees upside potential to their target of $29 on approval. Downside is to $6 if an 'approvable letter' is issued. It maintained a Neutral as it awaits the longer term IMPAC trial.
disclaimer: long Dendreon calls.